A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. (Q37878478)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604979%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

review article

1 reference

title

A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604979%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604979%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Ee Lyn Su

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604979%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

1 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604979%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Vaccines

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604979%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604979%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604979%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

575-588

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604979%20AND%20SRC:MED&resulttype=core&format=json

Global epidemiology of meningococcal disease.

1 February 2020

cites work

1 reference

Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis

21 January 2018

1 reference

Challenges and progress in the development of a serogroup B meningococcal vaccine

21 January 2018

1 reference

Review of meningococcal group B vaccines

21 January 2018

1 reference

Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years

21 January 2018

1 reference

The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.

21 January 2018

1 reference

Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.

21 January 2018

1 reference

Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit.

21 January 2018

1 reference

Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents

21 January 2018

1 reference

Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles

21 January 2018

1 reference

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.

21 January 2018

1 reference

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

21 January 2018

1 reference

Vaccine potential of the Neisseria meningitidis 2086 lipoprotein

21 January 2018

1 reference

Factor H-binding protein, a unique meningococcal vaccine antigen.

21 January 2018

1 reference

Complement. First of two parts

21 January 2018

1 reference

Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine

21 January 2018

1 reference

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates

21 January 2018

1 reference

Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus

21 January 2018

1 reference

Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate

21 January 2018

1 reference

Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine

21 January 2018

1 reference

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.

21 January 2018

1 reference

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

21 January 2018

1 reference

A universal vaccine for serogroup B meningococcus

21 January 2018

1 reference

NadA, a novel vaccine candidate of Neisseria meningitidis

21 January 2018

1 reference

Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells.

21 January 2018

1 reference

NadA diversity and carriage in Neisseria meningitidis

21 January 2018

1 reference

Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales

21 January 2018

1 reference

Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans

21 January 2018

1 reference

Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity

21 January 2018

1 reference

Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial

21 January 2018

1 reference

Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningoc

21 January 2018

1 reference

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

21 January 2018

1 reference

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.

21 January 2018

1 reference

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

21 January 2018

1 reference

Genetic Analysis of Meningococci Carried by Children and Young Adults

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.11.32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604979%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference